参考文献/References:
[1] Roth GA,Mensah GA,Johnson CO,et al. Global burden of cardiovascular diseases and risk factors,1990-2019:update from the GBD 2019 Study[J]. J Am Coll Cardiol,2020,76(25):2982-3021.
[2] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2022概要[J]. 中国循环杂志,2023,38(6):583-612.
[3] Dhindsa DS,Sandesara PB,Shapiro MD,et al. The evolving understanding and approach to residual cardiovascular risk management[J]. Front Cardiovasc Med ,2020,7:88.
[4] Ridker PM,Bhatt DL,Pradhan AD,et al.?Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy:a collaborative analysis of three randomised trials[J]. Lancet,2023,401(10384):1293-1301.
[5] Dalbeth N,Lauterio TJ,Wolfe HR. Mechanism of action of colchicine in the treatment of gout[J]. Clin Ther,2014,36(10):1465-1479.
[6] Gagné V,Marois L,Levesque JM,et al.?Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor:potential therapeutic implications[J]. Arthritis Res Ther,2013,15(4):R73.
[7] Lu N,Cheng W,Liu D,et al.?NLRP3-mediated inflammation in atherosclerosis and associated therapeutics[J]. Front Cell Dev Biol,2022,10:823387.
[8] Martínez GJ,Celermajer DS,Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation[J]. Atherosclerosis,2018,269:262-271.
[9] Guan T,Gao B,Chen G,et al. Colchicine attenuates renal injury in a model of hypertensive chronic kidney disease[J]. Am J Physiol Renal Physiol,2013,305(10):F1466-F1476.
[10] Sandbo N,Ngam C,Torr E,et al. Control of myofibroblast differentiation by microtubule dynamics through a regulated localization of mDia2[J]. J Biol Chem,2013,288(22):15466-15473.
[11] Pennings GJ,Reddel CJ,Chen VM,et al. Perspective:Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease[J]. Front Cardiovasc Med,2022,9:1104744.
[12] Niel E,Scherrmann JM. Colchicine today[J]. Joint Bone Spine,2006,73(6):672-678.
[13] Chappey O,Scherrmann JM.?[Colchicine:recent data on pharmacokinetics and clinical pharmacology][J]. Rev Med Interne,1995,16(10):782-789.
[14] Yang LP. Oral colchicine (Colcrys):in the treatment and prophylaxis of gout[J]. Drugs,2010,70(12):1603-1613.
[15] Slobodnick A,Shah B,Krasnokutsky S,et al. Update on colchicine,2017[J]. Rheumatology (Oxford),2018,57(suppl_1):i4-i11.
[16] Ozen F,Silan C,Uludag A,et al. Association between ABCB1 (MDR1) gene 3435 C＞T polymorphism and colchicine unresponsiveness of FMF patients[J]. Ren Fail,2011,33(9):899-903.
[17] Kofler T,Kurmann R,Lehnick D,et al. Colchicine in patients with coronary artery disease:a systematic review and meta-analysis of randomized trials[J]. J Am Heart Assoc,2021,10(16):e021198.
[18] Nidorf SM,Fiolet ATL,Mosterd A,et al.?Colchicine in patients with chronic coronary disease[J]. N Engl J Med,2020,383(19):1838-1847.
[19] Nidorf SM,Ben-Chetrit E,Ridker PM.?Low-dose colchicine for atherosclerosis:long-term safety[J]. Eur Heart J,2024,45(18):1596-1601.
[20] Chen T,Liu G,Yu B.?A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease[J]. Clin Res Cardiol,2023,112(11):1487-1505.
[21] Fiolet ATL,Opstal TSJ,Mosterd A,et al. Efficacy and safety of low-dose colchicine in patients with coronary disease:a systematic review and meta-analysis of randomized trials[J]. Eur Heart J,2021,42(28):2765-2775.
[22] Diaz-Arocutipa C,Benites-Meza JK,Chambergo-Michilot D,et al.?Efficacy and safety of colchicine in post-acute myocardial infarction patients:a systematic review and meta-analysis of randomized controlled trials[J]. Front Cardiovasc Med,2021,8:676771.
[23] Robinson PC,Terkeltaub R,Pillinger MH,et al. Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease[J]. Am J Med,2022,135(1):32-38.
[24] Langevitz P,Livneh A,Neumann L,et al.?Prevalence of ischemic heart disease in patients with familial Mediterranean fever[J]. Isr Med Assoc J,2001,3(1):9-12.
[25] Nidorf SM,Eikelboom JW,Budgeon CA,et al. Low-dose colchicine for secondary prevention of cardiovascular disease[J]. J Am Coll Cardiol, 2013,61(4):404-410.
[26] Tardif JC,Kouz S,Waters DD,et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med,2019,381(26):2497-2505.
[27] Tong DC,Quinn S,Nasis A,et al.?Colchicine in patients with acute coronary syndrome:the Australian COPS randomized clinical trial[J]. Circulation,2020,142(20):1890-1900.
[28] Tong DC,Bloom JE,Quinn S,et al.?Colchicine in patients with acute coronary syndrome:two-year follow-up of the Australian COPS randomized clinical trial[J]. Circulation,2021,144(19):1584-1586.
[29] Opstal TSJ,Fiolet ATL,van Broekhoven A,et al. Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome[J]. J Am Coll Cardiol,2021,78(9):859-866.
[30] Vaidya K,Arnott C,Martínez GJ,et al. Colchicine therapy and plaque stabilization in patients with acute?coronary syndrome:a CT coronary angiography study[J]. JACC Cardiovasc Imaging,2018,11(2 Pt 2):305-316.
[31] Yu M,Yang Y,Dong SL,et al. Effect of colchicine on coronary plaque stability in acute coronary syndrome as assessed by optical coherence tomography:the COLOCT randomized clinical trial[J]. Circulation,2024,150(13):981-993.
[32] Writing Committee;Bass TA,Abbott JD,et al.?2023 ACC/AHA/SCAI Advanced Training Statement on Interventional Cardiology (Coronary,Peripheral Vascular,and Structural Heart Interventions):A Report of the ACC Competency Management Committee[J]. JACC Cardiovasc Interv,2023,16(10):1239-1291.
[33] Zhou Y,Chen Z,Ma J,et al.Incidence,predictors and clinical significance of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention[J]. J Cardiol,2020,76(3):309-316.
[34] Deftereos S,Giannopoulos G,Angelidis C,et al.?Anti-inflammatory treatment with colchicine in acute myocardial infarction:a pilot study[J]. Circulation,2015,132(15):1395-1403.
[35] Deftereos S,Giannopoulos G,Raisakis K,et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients[J]. J Am Coll Cardiol,2013,61(16):1679-1685.
[36] Shah B,Pillinger M,Zhong H,et al.?Effects of acute colchicine administration prior to percutaneous coronary intervention:COLCHICINE-PCI randomized trial[J]. Circ Cardiovasc Interv,2020,13(4):e008717.
[37] Cole J,Htun N,Lew R,et al. COlchicine to Prevent PeriprocEdural Myocardial Injury in Percutaneous Coronary Intervention (COPE-PCI):Coronary Microvascular Physiology Pilot Substudy[J]. J Interv Cardiol,2022,2022:1098429.
[38] Hennessy T,Soh L,Bowman M,et al.?The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study:a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction[J]. Am Heart J,2019,215:62-69.
[39] Stewart S,Yang KCK,Atkins K,et al. Adverse events during oral colchicine use:a systematic review and meta-analysis of randomised controlled trials[J]. Arthritis Res Ther,2020,22(1):28.
[40] Opstal TSJ,Nidorf SM,Fiolet ATL,et al. Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial[J]. Int J Cardiol,2023,372:1-5.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(3):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(3):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(3):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(3):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(3):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(3):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(3):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(3):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]